Remission versus response as the goal of therapy in ADHD: A new standard for the field?

Clinical Therapeutics

Volumn 28, Issue 11, 2006, Pages 1892-1908

  Steele, Margaret ^a   Jensen, Peter S ^b   Quinn, Declan M P ^c  

^a WESTERN UNIVERSITY   (Canada)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

amphetamine; atomoxetine; attention deficit hyperactivity disorder; controlled release system; methylphenidate; oral; osmotic; remission; response

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; IMIPRAMINE; METHYLPHENIDATE; NORTRIPTYLINE; PEMOLINE; PLACEBO;

ACADEMIC ACHIEVEMENT; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; COMMUNITY CARE; CONTROLLED DRUG RELEASE; COST OF ILLNESS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RELEASE; DRUG RESPONSE; HEALTH CARE COST; HUMAN; HYPERACTIVITY; IMPULSIVENESS; MEDICAL LITERATURE; MEDLINE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; REMISSION; SOCIAL PSYCHOLOGY; SYMPTOM; TREATMENT FAILURE; TREATMENT OUTCOME;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; RECOVERY OF FUNCTION; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 33845956869     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.11.006     Document Type: Article

References (82)

1. American Academy of Pediatrics. Clinical practice guideline: Diagnosis and evaluation of the child with attentiondeficit/hyperactivity disorder. Pediatrics 105 (2000) 1158-1170
2. Elia J., Ambrosini P.J., and Rapoport J.L. Treatment of attentiondeficit-hyperactivity disorder. N Engl J Med. 340 (1999) 780-788
3. Brown R.T., Freeman W.S., Perrin J.M., et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 107 (2001) E43
4. Wolraich M.L., Hannah J.N., Baumgaertel A., and Feurer I.D. Examination of DSM-IV criteria for attention deficit/hyperactivity disorder in a countywide sample. J Dev Behav Pediatr. 19 (1998) 162-168
5. Barbaresi W., Katusic S., Colligan R., et al. How common is attentiondeficit/hyperactivity disorder? Towards resolution of the controversy: Results from a population-based study. Acta Paediatr Suppl. 93 (2004) 55-59
6. [published correction appears in J Am Acad Child Adolesc Psychiatry. 1997;36:1783]. Gaub M., and Carlson C.L. Gender differences in ADHD: A meta-analysis and critical review. J Am Acad Child Adolesc Psychiatry 36 (1997) 1036-1045
7. American Psychiatric Association. Diagnostic and Statistical Manual ofMental Disorders. 4th ed (1994), American Psychiatric Association, Washington, DC
8. Jensen P.S., Martin D., and Cantwell D.P. Comorbidity in ADHD: Implications for research, practice, and DSM-V. J Am Acad Child Adolesc Psychiatry 36 (1997) 1065-1079
9. Pliszka S., Carlson C., and Swanson J. ADHD with Co-Morbid Disorders Clinical Assessment and Management (1999), Guilford Press, New York, NY
10. Wolraich M.L., Hannah J.N., Pinnock T.Y., et al. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry 35 (1996) 319-324
11. Angold A., Costello E.J., and Erkanli A. Comorbidity. J Child Psychol Psychiatry 40 (1999) 57-87
12. Biederman J., Faraone S., Milberger S., et al. Predictors of persistence and remission of ADHD into adoles cence: Results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 35 (1996) 343-351
13. Barkley R.A., Anastopoulos A.D., Guevremont D.C., and Fletcher K.E. Adolescents with ADHD: Patterns of behavioral adjustment, academic functioning, and treatment utilization. J Am Acad Child Adolesc Psychiatry 30 (1991) 752-761
14. Moffitt T.E. Juvenile delinquency and attention deficit disorder: Boys' developmental trajectories from age 3 to age 15. Child Dev 61 (1990) 893-910
15. Fergusson D.M., Horwood L.J., and Lynskey M.T. The effects of conduct disorder and attention deficit in middle childhood on offending and scholastic ability at age 13. J Child Psychol Psychiatry 34 (1993) 899-916
16. Barkley R.A., Fischer M., Edelbrock C.S., and Smallish L. The adolescent outcome of hyperactive children diag nosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 29 (1990) 546-557
17. Weiss G., Hechtman L., Milroy T., and Perlman T. Psychiatric status of hyperactives as adults: A controlled pros pective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry 24 (1985) 211-220
18. Barkley R.A., Fischer M., Smallish L., and Fletcher K. Young adult outcome of hyperactive children: Adaptive func tioning in major life activities. J Am Acad Child Adolesc Psychiatry 45 (2006) 192-202
19. [published correction appears in J Abnorm Child Psychol. 2003;31:563]. Fischer M., Barkley R.A., Smallish L., and Fletcher K. Young adult follow-up of hyperactive children: Self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol 30 (2002) 463-475
20. Satterfield J.H., and Schell A. A prospective study of hyperactive boys with conduct problems and normal boys: Adolescent and adult criminality. J Am Acad Child Adolesc Psychiatry 36 (1997) 1726-1735
21. Biederman J., Wilens T., Mick E., et al. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): Effects of ADHD and psychiatric comorbidity. Am J Psychiatry 152 (1995) 1652-1658
22. Mannuzza S., Klein R.G., Bessler A., et al. Educational and occupational outcome of hyperactive boys grown up. J Am Acad ChildAdolesc Psychiatry 36 (1997) 1222-1227
23. Murphy K., and Barkley R.A. Attention deficit hyperactivity disorder adults: Comorbidities and adaptive impairments. Compr Psychiatry 37 (1996) 393-401
24. Mitchell E.A., Aman M.G., Turbott S.H., and Manku M. Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clin Pediatr (Phila) 26 (1987) 406-411
25. Barkley R.A., Guevremont D.C., Anastopoulos A.D., et al. Drivingrelated risks and outcomes of atten tion deficit hyperactivity disorder in adolescents and young adults: A 3to 5-year follow-up survey. Pediatrics 92 (1993) 212-218
26. Swensen A.R., Birnbaum H.G., Secnik K., et al. Attention-deficit/hyperactivity disorder: Increased costs for pa tients and their families. J Am Acad Child Adolesc Psychiatry 42 (2003) 1415-1423
27. Biederman J., Mick E., and Faraone S.V. Normalized functioning in youths with persistent attention-deficit/hyperactivity disorder. J Pediatr 133 (1998) 544-551
28. The MTA Cooperative Group (Multimodal Treatment Study of Children with ADHD). A 14-month random ized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56 (1999) 1073-1086
29. Swanson J.M., Wigal S.B., Wigal T., et al., COMACS Study Group. A comparison of once-daily extended release methylphenidate formulations in children with attention-deficit/ hyperactivity disorder in the laboratory school (the COMACS Study). Pediatrics 113 (2004) e206-e216
30. Hechtman L., Abikoff H., Klein R.G., et al. Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 43 (2004) 812-819
31. Swanson J., Gupta S., Lam A., et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: Proof-ofconcept and proof-of-product studies. Arch Gen Psychiatry 60 (2003) 204-211
32. Biederman J. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: Findings from a longitudinal follow-up of youths with and without ADHD. J Clin Psychiatry 64 Suppl 11 (2003) 3-8
33. Wilens T.E., Faraone S.V., Biederman J., and Gunawardene S. Does stimulant therapy of attention-deficit/hyper activity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111 (2003) 179-185
34. Steele M., Weiss M., Swanson J., et al. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediaterelease methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol. 13 (2006) e50-e62
35. Lage M., and Hwang P. Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J Child Adolesc Psychopharmacol 14 (2004) 575-581
36. Cox D.J., Merkel R.L., Penberthy J.K., et al. Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/ hyperactivity disorder: A pilot study. J Am Acad Child Adolesc Psychiatry 43 (2004) 269-275
37. Washington, DC. Abstract NR452. Cox D., Humphrey J., Merkel R., et al. Once-daily OROS MPH effects on reallife driving in adolescents with ADHD. Presented at: New Research Abstracts, Annual Meeting of the American Psychiatric Association (May 1-6, 2004)
38. Swanson J.M., Kraemer H.C., Hinshaw S.P., et al. Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 40 (2001) 168-179
39. Pliszka S.R., Greenhill L.L., Crismon M.L., et al. The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part I. Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 39 (2000) 908-919
40. Pliszka S. Review and update of practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. In: Sexson S., and Russel A. (Eds). Mid-Year Institute on Maintenance of Certification. Review of Maintenance of Certification. Module 1: Disruptive Behavior Disorders, Violence and Homicide (2005), American Academy of Child and Adolescent Psychiatry, La Jolla, Calif
41. Frank E., Prien R.F., Jarrett R.B., et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48 (1991) 851-855
42. (Suppl). Kupfer D.J. Long-term treatment of depression. J Clin Psychiatry 52 (1991) 28-34
43. Paykel E.S., Ramana R., Cooper Z., et al. Residual symptoms after partial remission: An important outcome in depression. Psychol Med. 25 (1995) 1171-1180
44. Miller I.W., Keitner G.I., Schatzberg A.F., et al. The treatment of chronic depression, part 3: Psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry. 59 (1998) 608-619
45. Simon G.E., Revicki D., Heiligenstein J., et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 22 (2000) 153-162
46. Kennedy S., McIntyre R., Fallu A., and Lam R. Pharmacotherapy to sustain the fully remitted state. J Psychiatry Neurosci 27 (2002) 269-280
47. Lam R.W., and Kennedy S.H. Evidencebased strategies for achieving and sustaining full remission in depression: Focus on metaanalyses. Can J Psychiatry 49 Suppl 1 (2004) 17S-26S
48. McIntyre R., Kennedy S., Bagby R.M., and Bakish D. Assessing full remission. J Psychiatry Neurosci. 27 (2002) 235-239
49. Judd L.L., Schettler P.J., and Akiskal H.S. The prevalence, clinical relevance, and public health significance of subthreshold depressions. Psychiatr Clin North Am. 25 (2002) 685-698
50. Swanson J. SNAP-IV Scale (1995), University of California, Irvine Child Development Center, Irvine, Calif
51. DuPaul G., Reid R., Power T., and Anastopoulos A. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations (1998), Guilford Publications, Inc, New York, NY
52. Stein M.A., Sarampote C.S., Waldman I.D., et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 112 (2003) e404
53. Guy W. ECDEU: Assessment Manual for Psychopharmacolog, Revised. (1976), US Department of Health, Education, and Welfare, Rockville, Md
54. Michelson D., Allen A.J., Busner J., et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebocontrolled study. Am J Psychiatry. 159 (2002) 1896-1901
55. Kelsey D.K., Sumner C.R., Casat C.D., et al. Once-daily atomoxetine treatment for children with attention deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial. Pediatrics 114 (2004) e1-e8
56. Conners C. Conners' Rating Scale-Revised (1997), MultiHealth Systems, North Tonawanda, NY
57. Washington, DC. Abstract NR480. Greenhill L., Wan G., and Cooper K. Remission of ADHD symptoms with stimulant therapy. Presented at: New Research Abstracts, Annual Meeting of the American Psychiatric Association (May 1-6, 2004)
58. Spencer T., Biederman J., Wilens T., et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 58 (2001) 775-782
59. Spencer T., Heiligenstein J., Biederman J., et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63 (2002) 1140-1147
60. Kemner J.E., Starr H.L., Ciccone P.E., et al. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: A multicenter, randomized prospective trial. Adv Ther. 22 (2005) 498-512
61. Wigal S.B., McGough J.J., McCracken J.T., et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in schoolaged children with attention deficit/ hyperactivity disorder. J Atten Disord 9 (2005) 275-289
62. Pelham W.E., Gnagy E.M., Burrows-Maclean L., et al. Once-a-day Concerta methylphenidate versus three times-daily methylphenidate in laboratory and natural settings. Pediatrics 107 (2001) E105
63. Efron D., Jarman F., and Barker M. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial. Pediatrics 100 (1997) E6
64. Ahmann P.A., Theye F.W., Berg R., et al. Placebo-controlled evaluation of amphetamine mixture-dextroampheta mine salts and amphetamine salts (Adderall): Efficacy rate and side effects. Pediatrics 107 (2001) E10
65. Weiss M., Tannock R., Kratochvil C., et al. A randomized, placebocontrolled study of once-dailyatom oxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 44 (2005) 647-655
66. Greenhill L.L., Swanson J.M., Vitiello B., et al. Impairment and deportment responses to different methylpheni date doses in children with ADHD: The MTA titration trial. J Am Acad Child Adolesc Psychiatry 40 (2001) 180-187
67. Hechtman L., and Greenfield B. Longterm use of stimulants in children with attention deficit hyperactivity disorder: Safety, efficacy, and longterm outcome. Paediatr Drugs 5 (2003) 787-794
68. Washington, DC. Abstract NR436. Steele M., Prinzo R., and Binder C. Longterm effectiveness and safety of Concerta in children with ADHD: A six-month study. Presented at: New Research Abstracts, Annual Meeting of the American Psychiatric Association (May 21-26, 2005)
69. Washington, DC. Abstract NR434. Steele M., Prinzo R., and Binder C. The maintenance of effectiveness of Concerta in children with ADHD: An eight-month analysis. Presented at: New Research Abstracts, Annual Meeting of the American Psychiatric Association (May 21-26, 2005)
70. Barkley R. Attention-Deficit Hyperactivity Disorder. A Handbook for Diagnosis and Treatment. 2nd ed (1998), Guilford Press, New York, NY
71. Weiss G., and Hechtman L. Hyperactive Children Grown Up. 2nd ed (1993), Guilford Press, New York, NY
72. Hechtman L., Weiss G., and Perlman T. Young adult outcome of hyperactive children who received long-term stimulant treatment. J Am Acad Child Psychiatry 23 (1984) 261-269
73. Biederman J., Faraone S., Milberger S., et al. A prospective 4-year followup study of attention-deficit hyper-activity and related disorders. Arch Gen Psychiatry 53 (1996) 437-446
74. Biederman J., Wilens T., Mick E., et al. Pharmacotherapy of attention-deficit/ hyperactivity disorder reduces risk for substance use disorder. Pediatrics 104 (1999) e20
75. Mannuzza S., Klein R.G., Bessler A., et al. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 50 (1993) 565-576
76. Abikoff H., Hechtman L., Klein R.G., et al. Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 43 (2004) 802-811
77. Pelham W.E., Aronoff H.R., Midlam J.K., et al. A comparison of Ritalin and Adderall: Efficacy and time-course in children with attention-deficit/hyperactivity disorder. Pediatrics 103 (1999) e43
78. Wolraich M.L., Greenhill L.L., Pelham W., et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attentiondeficit/hyperactivity disorder. Pediatrics 108 (2001) 883-892
79. Washington, DC. Abstract NR435. Steele M., Prinzo R., and Binder C. Effectiveness of OROS methylphenidate vs. usual care immediate release methylphenidate on co-morbid oppositional defiant disorder symptoms in ADHD children. Presented at: New Research Abstracts, Annual Meeting of the American Psychiatric Association (May 21-26, 2005)
80. Washington, DC. Abstract NR506. Cox D., Merkel R., Moore M., et al. The relative benefits of OROS MPH versus Se-AMPH extended release in driving safety of teenagers with ADHD. Presented at: New Research Abstracts, Annual Meeting of the American Psychiatric Association (May 21-26, 2005)
81. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: Changes in effectiveness and growth after the end of treatment. Pediatrics 113 (2004) 762-769
82. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-Month outcomes of treatment strategies for attentiondeficit/hyperactivity disorder. Pediatrics 113 (2004) 754-761